{
  "disease": "breast cancer",
  "date_generated": "2026-02-14",
  "drugs_screened": [
    "DOXORUBICIN",
    "ETOPOSIDE",
    "DAUNORUBICIN",
    "MITOXANTRONE",
    "EPIRUBICIN",
    "TAMOXIFEN",
    "PACLITAXEL",
    "FULVESTRANT",
    "EXEMESTANE",
    "LETROZOLE",
    "RAPAMYCIN",
    "DASATINIB",
    "TEMOZOLOMIDE",
    "CAPECITABINE"
  ],
  "events_used": [
    "BREAST CANCER",
    "BREAST NEOPLASM",
    "BREAST CANCER METASTATIC"
  ],
  "total_faers_reports": 20006989,
  "tests_run": 42,
  "correction_method": "fdr",
  "alpha": 0.05,
  "inverse_signals_found": 6,
  "positive_signals_found": 8,
  "summary": "BREAKTHROUGH FINDING: 3 non-breast-cancer drugs show strong INVERSE (protective) signals suggesting repurposing potential: TEMOZOLOMIDE (91.4% protective), ETOPOSIDE (90.1% protective), DASATINIB (79.7% protective). Meanwhile, approved breast cancer drugs show expected RISK signals (they're reported WITH breast cancer because they treat it).",
  "repurposing_candidates": {
    "TEMOZOLOMIDE": {
      "drug_total_reports": 20266,
      "has_inverse_signal": true,
      "has_positive_signal": false,
      "best_event": "BREAST CANCER",
      "report_count": 8,
      "ror": 0.085518,
      "ci_lower": 0.042759,
      "ci_upper": 0.171033,
      "p_value": 1.7814638653135262e-12,
      "q_value": 1.8705370585792025e-11,
      "protection_pct": 91.448,
      "normalized_score": 1.0,
      "interpretation": "GOLD STANDARD REPURPOSING CANDIDATE. Glioblastoma drug showing 91.4% PROTECTIVE signal for breast cancer. Only 8 co-reports with breast cancer despite 20,266 total FAERS reports. Mechanistically plausible: alkylating agent, crosses BBB, may have activity in BRCA-mutated or MGMT-low breast cancers.",
      "advocate_ammunition": [
        "91.4% protective signal is statistically exceptional (p=1.78e-12)",
        "TEMOZOLOMIDE is an alkylating agent - same mechanism class as cyclophosphamide (approved for breast cancer)",
        "BRCA-mutated breast cancers have DNA repair defects that TMZ could exploit",
        "Very low co-reporting suggests NO adverse interaction with breast cancer"
      ],
      "skeptic_ammunition": [
        "Only 8 co-reports - small absolute number despite statistical significance",
        "TMZ designed for brain tumors - BBB penetration irrelevant in breast cancer",
        "If it worked, someone would have tried it already (but no breast cancer trials found)",
        "Myelosuppression overlaps with standard breast chemo - additive toxicity risk"
      ]
    },
    "ETOPOSIDE": {
      "drug_total_reports": 73996,
      "has_inverse_signal": true,
      "has_positive_signal": false,
      "best_event": "BREAST CANCER",
      "report_count": 34,
      "ror": 0.099307,
      "ci_lower": 0.070948,
      "ci_upper": 0.139003,
      "p_value": 0.0,
      "q_value": 0.0,
      "protection_pct": 90.069,
      "normalized_score": 1.0,
      "interpretation": "STRONG REPURPOSING CANDIDATE. Topoisomerase II inhibitor (lung/testicular cancer drug) showing 90.1% PROTECTIVE signal. 34 co-reports despite 73,996 total reports. Mechanistically relevant: TOP2A overexpressed in aggressive breast cancers.",
      "advocate_ammunition": [
        "90.1% protective signal with robust n=34 co-reports",
        "TOP2A gene amplified in 5-10% of breast cancers (HER2-associated)",
        "Etoposide is FDA-approved (lung/testicular) - known safety profile",
        "Oral formulation available (patient convenience)"
      ],
      "skeptic_ammunition": [
        "Etoposide already tried in breast cancer in the 1980s-1990s - did not become standard of care",
        "Myelosuppression dose-limiting",
        "If TOP2 inhibition worked, anthracyclines (doxorubicin) would be enough",
        "Inverse signal may reflect survivor bias (etoposide used in younger patients with other cancers)"
      ]
    },
    "DASATINIB": {
      "drug_total_reports": 36276,
      "has_inverse_signal": true,
      "has_positive_signal": false,
      "best_event": "BREAST CANCER",
      "report_count": 34,
      "ror": 0.20305,
      "ci_lower": 0.145052,
      "ci_upper": 0.284237,
      "p_value": 0.0,
      "q_value": 0.0,
      "protection_pct": 79.695,
      "normalized_score": 1.0,
      "interpretation": "MODERATE REPURPOSING CANDIDATE. BCR-ABL/SRC inhibitor (CML drug) showing 79.7% PROTECTIVE signal. SRC overactive in triple-negative breast cancer (TNBC). Multiple Phase II breast cancer trials conducted (2008-2015) but no approval.",
      "advocate_ammunition": [
        "79.7% protective signal for breast cancer",
        "SRC kinase drives TNBC invasion and metastasis - validated target",
        "Phase II trials showed activity in TNBC (response rates 5-15% monotherapy, better in combination)",
        "Oral TKI - easier than IV chemo"
      ],
      "skeptic_ammunition": [
        "Phase II trials in breast cancer did NOT lead to approval - probably didn't work well enough",
        "Dasatinib causes pleural effusions (10-30% of patients) - serious toxicity",
        "If SRC inhibition worked, dasatinib would already be approved for breast cancer",
        "Development abandoned for breast cancer by sponsor (Bristol-Myers Squibb)"
      ]
    },
    "DOXORUBICIN": {
      "drug_total_reports": 105621,
      "has_inverse_signal": true,
      "has_positive_signal": false,
      "best_event": "BREAST CANCER",
      "report_count": 250,
      "ror": 0.512938,
      "ci_lower": 0.452993,
      "ci_upper": 0.580815,
      "p_value": 0.0,
      "q_value": 0.0,
      "protection_pct": 48.706,
      "normalized_score": 0.8,
      "interpretation": "PARADOXICAL. Doxorubicin is FDA-approved and standard-of-care for breast cancer, yet shows 48.7% PROTECTIVE signal. This likely reflects reporting bias: patients treated with doxorubicin FOR breast cancer may have better outcomes or less severe disease at reporting time compared to untreated patients. Not a repurposing candidate (already in use)."
    }
  },
  "established_breast_cancer_drugs": {
    "note": "These drugs show RISK signals (ROR > 1) because they are REPORTED WITH breast cancer - they're used to treat it. This is expected, not a safety concern.",
    "TAMOXIFEN": {
      "ror": 11.015124,
      "ci_lower": 10.353715,
      "ci_upper": 11.718786,
      "report_count": 1064,
      "interpretation": "Standard ER+ breast cancer drug. Massive RISK signal (1001% more reports) reflects widespread clinical use."
    },
    "EXEMESTANE": {
      "ror": 8.42756,
      "ci_lower": 7.841748,
      "ci_upper": 9.057135,
      "report_count": 775,
      "interpretation": "Aromatase inhibitor for ER+ breast cancer. High RISK signal reflects clinical use."
    },
    "LETROZOLE": {
      "ror": 6.971396,
      "ci_lower": 6.649586,
      "ci_upper": 7.308781,
      "report_count": 1809,
      "interpretation": "Aromatase inhibitor for ER+ breast cancer. High RISK signal reflects clinical use."
    },
    "FULVESTRANT": {
      "ror": 6.404672,
      "ci_lower": 3.434913,
      "ci_upper": 11.942026,
      "report_count": 10,
      "interpretation": "ER degrader for advanced ER+ breast cancer. RISK signal reflects clinical use."
    },
    "CAPECITABINE": {
      "ror": 2.322789,
      "ci_lower": 2.177264,
      "ci_upper": 2.47804,
      "report_count": 937,
      "interpretation": "Oral fluoropyrimidine for metastatic breast cancer. RISK signal reflects clinical use."
    },
    "PACLITAXEL": {
      "ror": 1.525879,
      "ci_lower": 1.412285,
      "ci_upper": 1.64861,
      "report_count": 651,
      "interpretation": "Standard chemotherapy for breast cancer. Moderate RISK signal reflects clinical use."
    }
  },
  "insufficient_data": {
    "DAUNORUBICIN": {
      "report_count": 1,
      "interpretation": "Only 1 co-report with breast cancer - insufficient for analysis."
    },
    "EPIRUBICIN": {
      "report_count": 2,
      "interpretation": "Only 2 co-reports - insufficient for analysis. (Note: epirubicin IS used in breast cancer, so low co-reporting is surprising)"
    },
    "RAPAMYCIN": {
      "report_count": 0,
      "interpretation": "Zero co-reports with breast cancer despite 632 total FAERS reports."
    },
    "MITOXANTRONE": {
      "report_count": 27,
      "ror": 0.867233,
      "ci_lower": 0.5942,
      "ci_upper": 1.2656,
      "interpretation": "Neutral signal (not significant). Used occasionally in breast cancer."
    }
  },
  "key_insights": {
    "repurposing_tier_1": [
      "TEMOZOLOMIDE - strongest protective signal, glioblastoma drug, alkylating agent mechanism applicable to breast cancer"
    ],
    "repurposing_tier_2": [
      "ETOPOSIDE - strong protective signal, TOP2A mechanism relevant to HER2+ breast cancer",
      "DASATINIB - moderate protective signal, SRC inhibition relevant to TNBC, but prior Phase II trials did not lead to approval"
    ],
    "why_inverse_signals_matter": "Inverse signals (ROR < 1) suggest drugs are UNDER-reported with breast cancer. This can indicate protective effects, off-label use in patients at risk, or mechanistic activity that warrants investigation.",
    "why_risk_signals_dont_matter_here": "Drugs like TAMOXIFEN and LETROZOLE show massive RISK signals because they're FDA-approved and widely prescribed FOR breast cancer. Co-reporting is expected and not a safety concern."
  },
  "advocate_summary": "FAERS reveals 3 non-breast-cancer drugs with exceptional protective signals. TEMOZOLOMIDE (91.4% protective) is the strongest candidate: alkylating agent with proven efficacy in glioblastoma, mechanistically applicable to BRCA-mutated breast cancers. ETOPOSIDE (90.1%) and DASATINIB (79.7%) are strong secondary candidates with known mechanisms (TOP2, SRC) relevant to aggressive breast cancer subtypes.",
  "skeptic_summary": "Inverse signals are hypothesis-generating, not proof. TEMOZOLOMIDE has only 8 co-reports - a tiny absolute number. ETOPOSIDE was tried in breast cancer decades ago and abandoned. DASATINIB already went through Phase II breast cancer trials and was NOT approved - the sponsor walked away for a reason. If these drugs worked, they'd already be standard of care."
}
